&nbsp;

Jan 2025

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin

... Show more tags

Quick Link(s):

Regimen Monograph

Jan 2025

Drug

glofitamab

Other Name(s): Columvi®

Quick Link(s):

Jan 2025

Drug

epcoritamab

Other Name(s): Epkinly™

Quick Link(s):

Jan 2025

Regimen

MFOLFOX6+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

FOLFIRI+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Drug

avelumab

Other Name(s): Bavencio™

Quick Link(s):

Jan 2025

Regimen

AVEL

Cancer Type:

Skin,

Merkel Cell

Intent: Palliative

Funding:

New Drug Funding Program

Avelumab - Metastatic Merkel Cell Carcinoma

Drugs Used:

avelumab

... Show more tags

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

AVEL(MNT)

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma

Drugs Used:

avelumab

... Show more tags

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CISPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CRBPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CAPECISP+PEMB; CAPE+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

ODB - General Benefit

capecitabine

Drugs Used: